-DOCSTART- -X- O
Cytomegalovirus -X- _ B-Intervention
( -X- _ I-Intervention
CMV -X- _ I-Intervention
) -X- _ I-Intervention
reactivation -X- _ I-Intervention
in -X- _ O
non-immune-suppressed -X- _ B-Patient
critically -X- _ I-Patient
ill -X- _ I-Patient
patients -X- _ I-Patient
is -X- _ O
an -X- _ O
area -X- _ O
of -X- _ O
increasing -X- _ O
interest. -X- _ O
CMV -X- _ O
has -X- _ O
long -X- _ O
been -X- _ O
appreciated -X- _ O
as -X- _ O
a -X- _ O
pathogen -X- _ O
in -X- _ O
immunocompromised -X- _ O
hosts. -X- _ O
CMV -X- _ B-Outcome
reactivates -X- _ I-Outcome
in -X- _ I-Outcome
approximately -X- _ I-Outcome
one-third -X- _ I-Outcome
of -X- _ I-Outcome
latently -X- _ I-Outcome
infected -X- _ I-Outcome
non-immune-suppressed -X- _ I-Outcome
hosts -X- _ I-Outcome
during -X- _ I-Outcome
critical -X- _ I-Outcome
illness -X- _ I-Outcome
; -X- _ O
however -X- _ O
, -X- _ O
its -X- _ O
role -X- _ O
as -X- _ O
a -X- _ O
pathogen -X- _ O
in -X- _ O
these -X- _ O
patients -X- _ O
remains -X- _ O
unclear. -X- _ O
CMV -X- _ B-Intervention
reactivation -X- _ I-Intervention
has -X- _ O
been -X- _ O
linked -X- _ O
to -X- _ O
bacterial -X- _ B-Outcome
sepsis -X- _ I-Outcome
and -X- _ O
likely -X- _ O
results -X- _ B-Outcome
from -X- _ I-Outcome
inflammation -X- _ I-Outcome
, -X- _ I-Outcome
transient -X- _ I-Outcome
immune -X- _ I-Outcome
compromise -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
viral -X- _ I-Outcome
epigenetic -X- _ I-Outcome
changes. -X- _ I-Outcome
While -X- _ O
CMV -X- _ O
may -X- _ O
improve -X- _ O
immune -X- _ O
response -X- _ O
to -X- _ O
some -X- _ O
bacterial -X- _ O
infections -X- _ O
, -X- _ O
other -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
CMV -X- _ O
induces -X- _ B-Outcome
exaggerated -X- _ I-Outcome
responses -X- _ I-Outcome
to -X- _ I-Outcome
severe -X- _ I-Outcome
infections -X- _ I-Outcome
that -X- _ O
may -X- _ O
be -X- _ O
harmful -X- _ O
to -X- _ O
latently -X- _ O
infected -X- _ O
hosts. -X- _ O
These -X- _ O
results -X- _ O
also -X- _ O
suggest -X- _ O
that -X- _ O
previous -X- _ O
infection -X- _ O
history -X- _ O
may -X- _ O
explain -X- _ O
significant -X- _ O
differences -X- _ O
seen -X- _ O
between -X- _ O
human -X- _ O
septic -X- _ O
responses -X- _ O
and -X- _ O
murine -X- _ O
models -X- _ O
of -X- _ O
sepsis. -X- _ O
While -X- _ O
critically -X- _ O
ill -X- _ O
human -X- _ O
hosts -X- _ O
clearly -X- _ O
have -X- _ O
worse -X- _ O
outcomes -X- _ O
associated -X- _ O
with -X- _ O
CMV -X- _ B-Intervention
reactivation -X- _ I-Intervention
, -X- _ O
determining -X- _ O
causality -X- _ O
remains -X- _ O
an -X- _ O
area -X- _ O
of -X- _ O
investigation -X- _ O
, -X- _ O
with -X- _ O
randomized -X- _ O
control -X- _ O
trials -X- _ O
currently -X- _ O
being -X- _ O
performed. -X- _ O
Here -X- _ O
we -X- _ O
review -X- _ O
the -X- _ O
current -X- _ O
literature -X- _ O
and -X- _ O
highlight -X- _ O
areas -X- _ O
for -X- _ O
future -X- _ O
investigation -X- _ O
. -X- _ O

